Scholarlink

Background <p>Nutritional or systemic inflammatory markers like modified Glasgow Prognostic Score (mGPS), prognostic nutritional index (PNI), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are useful prognostic indicators, but their role in patients with unresectable or metastatic biliary tract cancer receiving gemcitabine plus cisplatin (GC) or GC plus durvalumab is unclear. This study investigates the relationship of these markers with treatment outcomes and survival.</p> Methods <p>Chemotherapy consisted of protracted infusion of gemcitabine (1000 mg/m<sup>2</sup>/day) and cisplatin (25 mg/m<sup>2</sup>/day) on day 1 and 8, or gemcitabine (1000 mg/m<sup>2</sup>/day), cisplatin (25 mg/m<sup>2</sup>/day) on day 1 and 8 and durvalumab (1500 mg/day 1) given once every 21 days. After six cycles of GC plus durvalumab therapy, durvalumab monotherapy was administered at 1500 mg every 4 weeks. PNI, NLR, PLR and mGPS were assessed before treatment using established cutoffs. Overall survival (OS) and time to treatment failure (TTF) were analyzed with Kaplan–Meier and Cox regression models. The primary endpoint was OS, defined as the time from the start of chemotherapy to death.</p> Results <p>This study analyzed 103 patients with unresectable or metastatic biliary tract cancer treated with GC or GC plus durvalumab. For patients with PLR ≥ 148 the median survival was 13.7 months and for those with PLR &lt; 148 the median OS was not estimated; this difference was significant (<i>p</i> = 0.016). For patients with mGPS 0–1 and 2 the median OS was 16.9 months and 7.9 months, respectively, and this difference was also significant (<i>p</i> &lt; 0.001). Univariate analysis revealed that, among the nutritional or systemic inflammatory markers tested, mGPS 2 and PLR ≥ 148 significantly predicted shorter OS. Multivariate analysis further confirmed that mGPS 2 is an independent risk factor for shorter OS.</p> Conclusion <p>A mGPS of 2 was a predictor of shorter OS for patients with unresectable or metastatic biliary tract cancer receiving GC or GC plus durvalumab. Evaluating mGPS prior to treatment initiation may support planning of individualized treatments that can enable clinicians to identify patients who are likely to benefit from chemotherapy and to exercise caution when considering systemic therapy for those with mGPS 2.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Relationship of nutritional or systemic inflammatory markers with efficacy of gemcitabine and cisplatin with or without durvalumab therapy for patients with unresectable or metastatic biliary tract cancer: a retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月16日

查看全文
  • Yayoi Fukushi,
  • Kazuma Fujita,
  • Yumiko Akamine,
  • Haruka Igarashi,
  • Katsuya Sasaki,
  • Koji Fukuda,
  • Hiroyuki Shibata,
  • Masafumi Kikuchi

摘要

Background

Nutritional or systemic inflammatory markers like modified Glasgow Prognostic Score (mGPS), prognostic nutritional index (PNI), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are useful prognostic indicators, but their role in patients with unresectable or metastatic biliary tract cancer receiving gemcitabine plus cisplatin (GC) or GC plus durvalumab is unclear. This study investigates the relationship of these markers with treatment outcomes and survival.

Methods

Chemotherapy consisted of protracted infusion of gemcitabine (1000 mg/m2/day) and cisplatin (25 mg/m2/day) on day 1 and 8, or gemcitabine (1000 mg/m2/day), cisplatin (25 mg/m2/day) on day 1 and 8 and durvalumab (1500 mg/day 1) given once every 21 days. After six cycles of GC plus durvalumab therapy, durvalumab monotherapy was administered at 1500 mg every 4 weeks. PNI, NLR, PLR and mGPS were assessed before treatment using established cutoffs. Overall survival (OS) and time to treatment failure (TTF) were analyzed with Kaplan–Meier and Cox regression models. The primary endpoint was OS, defined as the time from the start of chemotherapy to death.

Results

This study analyzed 103 patients with unresectable or metastatic biliary tract cancer treated with GC or GC plus durvalumab. For patients with PLR ≥ 148 the median survival was 13.7 months and for those with PLR < 148 the median OS was not estimated; this difference was significant (p = 0.016). For patients with mGPS 0–1 and 2 the median OS was 16.9 months and 7.9 months, respectively, and this difference was also significant (p < 0.001). Univariate analysis revealed that, among the nutritional or systemic inflammatory markers tested, mGPS 2 and PLR ≥ 148 significantly predicted shorter OS. Multivariate analysis further confirmed that mGPS 2 is an independent risk factor for shorter OS.

Conclusion

A mGPS of 2 was a predictor of shorter OS for patients with unresectable or metastatic biliary tract cancer receiving GC or GC plus durvalumab. Evaluating mGPS prior to treatment initiation may support planning of individualized treatments that can enable clinicians to identify patients who are likely to benefit from chemotherapy and to exercise caution when considering systemic therapy for those with mGPS 2.